Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Nabanita, Nawar"'
Autor:
Harsimran Kaur Garcha, Nabanita Nawar, Helena Sorger, Fettah Erdogan, Myint Myat Khine Aung, Abootaleb Sedighi, Pimyupa Manaswiyoungkul, Hyuk-Soo Seo, Susann Schönefeldt, Daniel Pölöske, Sirano Dhe-Paganon, Heidi A. Neubauer, Satu M. Mustjoki, Marco Herling, Elvin D. de Araujo, Richard Moriggl, Patrick T. Gunning
Publikováno v:
Pharmaceuticals, Vol 15, Iss 11, p 1321 (2022)
NK/T-cell lymphoma (NKTCL) and γδ T-cell non-Hodgkin lymphomas (γδ T-NHL) are highly aggressive lymphomas that lack rationally designed therapies and rely on repurposed chemotherapeutics from other hematological cancers. Histone deacetylases (HDA
Externí odkaz:
https://doaj.org/article/87a893d2ff80432881eea8c588541e56
Autor:
Nabanita Nawar, Shazreh Bukhari, Ashley A. Adile, Yujin Suk, Pimyupa Manaswiyoungkul, Krimo Toutah, Olasunkanmi O. Olaoye, Yasir S. Raouf, Abootaleb Sedighi, Harsimran Kaur Garcha, Muhammad Murtaza Hassan, William Gwynne, Johan Israelian, Tudor B. Radu, Mulu Geletu, Ayah Abdeldayem, Justyna M. Gawel, Aaron D. Cabral, Chitra Venugopal, Elvin D. de Araujo, Sheila K. Singh, Patrick T. Gunning
Publikováno v:
Journal of Medicinal Chemistry. 65:3193-3217
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc016ee3578a633ee7c466b4bdc32cac
https://doi.org/10.1021/acs.jmedchem.1c01585
https://doi.org/10.1021/acs.jmedchem.1c01585
Autor:
Nabanita Nawar, Harsimran Kaur Garcha, Abootaleb Sedighi, Elvin D. de Araujo, Patrick T. Gunning
Publikováno v:
Methods in Molecular Biology ISBN: 9781071627877
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f3ab7279e261671340d8f74fab69a13
https://doi.org/10.1007/978-1-0716-2788-4_11
https://doi.org/10.1007/978-1-0716-2788-4_11
Autor:
Nabanita, Nawar, Harsimran Kaur, Garcha, Abootaleb, Sedighi, Elvin D, de Araujo, Patrick T, Gunning
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2589
The aberrant activity of histone deacetylases (HDACs) across a broad range of cancers and other disease indications has led to the development of small-molecule inhibitors that target one or more members of the HDAC protein family. Emerging HDAC inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bb39fbbc58dac644e36b47dedd0ae6de
https://pubmed.ncbi.nlm.nih.gov/36255624
https://pubmed.ncbi.nlm.nih.gov/36255624
Autor:
Andrew E. Shouksmith, Abootaleb Sedighi, Yasir S. Raouf, Niyati Kachhiyapatel, Ayah Abdeldayem, Paris R. Watson, Krimo Toutah, Olasunkanmi O. Olaoye, David W. Christianson, Patrick T. Gunning, Shazreh Bukhari, Pimyupa Manaswiyoungkul, Justyna M. Gawel, Aaron D. Cabral, Johan Israelian, Muhammad Murtaza Hassan, Nabanita Nawar, Fettah Erdogan, Elvin D. de Araujo, Tudor B. Radu, Mulu Geletu
Publikováno v:
J Med Chem
Histone deacetylase 6 (HDAC6) is involved in multiple regulatory processes, ranging from cellular stress to intracellular transport. Inhibition of aberrant HDAC6 activity in several cancers and neurological diseases has been shown to be efficacious i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9badc9098e407d7f5ed776a4126d1106
https://pubmed.ncbi.nlm.nih.gov/33576627
https://pubmed.ncbi.nlm.nih.gov/33576627
Autor:
Patrick T. Gunning, Yasir S. Raouf, Muhammad Murtaza Hassan, Jana von Jan, Aleksandr Ianevski, Muzaffar N. Bhatti, Justyna M. Gawel, Mulu Geletu, Pimyupa Manaswiyoungkul, Nabanita Nawar, Elvin D. de Araujo, Helena Sorger, Olasunkanmi O. Olaoye, Tero Aittokallio, Oliver H. Krämer, Marco Herling, Sanna Timonen, Ayah Abdeldayem, Krimo Toutah, Tudor B. Radu, Richard Moriggl, Shazreh Bukhari, Johan Israelian, Heidi A. Neubauer, Satu Mustjoki, Andrew E. Shouksmith, Abootaleb Sedighi
Publikováno v:
Journal of Medicinal Chemistry
Epigenetic targeting has emerged as an efficacious therapy for hematological cancers. The rare and incurable T-cell prolymphocytic leukemia (T-PLL) is known for its aggressive clinical course. Current epigenetic agents such as histone deacetylase (HD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e3a89d15e76dd9bd052d4a50193efb2
http://hdl.handle.net/10852/93204
http://hdl.handle.net/10852/93204
Autor:
Muhammad Murtaza Hassan, Yasir S. Raouf, Pimyupa Manaswiyoungkul, Aaron D. Cabral, Abootaleb Sedighi, Rabia Altintas, Fettah Erdogan, Patrick T. Gunning, Giovanni Ganda, David W.J. Armstrong, Olasunkanmi O. Olaoye, Elvin D. de Araujo, Johan Israelian, Fabrizio Angeles, Nabanita Nawar
Publikováno v:
Journal of medicinal chemistry. 63(15)
Histone deacetylases (HDACs) are an attractive therapeutic target for a variety of human diseases. Currently, all four FDA-approved HDAC-targeting drugs are nonselective, pan-HDAC inhibitors, exhibiting adverse side effects at therapeutic doses. Alth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::456714751dd802b91d1d0aa5585e2945
https://pubmed.ncbi.nlm.nih.gov/32672458
https://pubmed.ncbi.nlm.nih.gov/32672458
Autor:
Abootaleb Sedighi, Yasir S. Raouf, Diana Sina, Krimo Toutah, Johan Israelian, Andrew E. Shouksmith, Patrick T. Gunning, Shazreh Bukhari, Elvin D. de Araujo, Olasunkanmi O. Olaoye, Aaron D. Cabral, Nabanita Nawar, Tudor B. Radu, Justyna M. Gawel, Pimyupa Manaswiyoungkul
Publikováno v:
European journal of medicinal chemistry. 201
Dysregulated Histone Deacetylase (HDAC) activity across multiple human pathologies have highlighted this family of epigenetic enzymes as critical druggable targets, amenable to small molecule intervention. While efficacious, current approaches using
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6f8e10ab2f4288fa6181dfde142909e
https://pubmed.ncbi.nlm.nih.gov/32615502
https://pubmed.ncbi.nlm.nih.gov/32615502
Autor:
Elvin D. de Araujo, Andrew E. Shouksmith, Abootaleb Sedighi, Aaron D. Cabral, Patrick T. Gunning, Pimyupa Manaswiyoungkul, Diana Sina, Shazreh Bukhari, Yasir S. Raouf, Justyna M. Gawel, Liying He, Alexandra E. Johns, Nabanita Nawar, Olasunkanmi O. Olaoye
Publikováno v:
ACS Med Chem Lett
[Image: see text] The HDAC inhibitor 4-tert-butyl-N-(4-(hydroxycarbamoyl)phenyl)benzamide (AES-350, 51) was identified as a promising preclinical candidate for the treatment of acute myeloid leukemia (AML), an aggressive malignancy with a meagre 24%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8b6bfa2d897a97ac51dd37f2f9572b1
https://pubmed.ncbi.nlm.nih.gov/31938464
https://pubmed.ncbi.nlm.nih.gov/31938464
Autor:
Jeffrey R. Ahern, Marc T. J. Johnson, Juha-Pekka Salminen, Nabanita Nawar, Julia Glinos, Daniel N. Anstett
Publikováno v:
Ecology letters. 18(12)
Greater plant defence is predicted to evolve at lower latitudes in response to increased herbivore pressure. However, recent studies question the generality of this pattern. In this study, we tested for genetically based latitudinal clines in resista
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13e8d8224ec8caa2fc6dacb144bcac6d
https://pubmed.ncbi.nlm.nih.gov/26482702
https://pubmed.ncbi.nlm.nih.gov/26482702